Ipratropium bromide and Lucentis drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ipratropium bromide (ipratropium bromide) and Lucentis (ranibizumab). Common drug interactions include lung consolidation among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Ipratropium bromide and Lucentis. It is created by eHealthMe based on reports of 21 people who take the same drugs from the FDA, and is updated regularly.

What is Ipratropium bromide?

Ipratropium bromide has active ingredients of ipratropium bromide. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 17,965 Ipratropium bromide users. Check the latest studies of Ipratropium bromide.

What is Lucentis?

Lucentis has active ingredients of ranibizumab. It is often used in macular degeneration. eHealthMe is studying from 25,647 Lucentis users. Check the latest studies of Lucentis.

On Jul, 27, 2026

21 people who take Ipratropium bromide and Lucentis together, and have interactions are studied.

Ipratropium bromide and Lucentis drug interactions.

What are the common drug interactions of Ipratropium Bromide and Lucentis, by gender? *:

female:

Lung consolidation (a condition whereby the lung tissues solidify because of the accumulation of solid and liquid material in the air spaces)
Musculoskeletal discomfort (discomfort in the body's muscles, joints, tendons, ligaments and nerves)
Pleural effusion (water on the lungs)
Pseudomonas infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa)
Pulmonary oedema (fluid accumulation in the lungs)
Renal disorder (kidney disease)
Sinus bradycardia (an unusually slow heartbeat due to heart disease)
Sputum culture positive
Tardive dyskinesia (a disorder that involves involuntary movements)
Thrombocytopenia (decrease of platelets in blood)

male:

Death
Back pain
Heart rate irregular
Hypoaesthesia (reduced sense of touch or sensation)
Irritability
Joint swelling
Maculopathy (a condition or disease of the macula, the small spot in the retina where vision is keenest)
Muscular weakness (muscle weakness)
Polydipsia (excessive thirst)
Retinal haemorrhage (bleeding from retina)

What are the common drug interactions of Ipratropium Bromide and Lucentis, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

Fatigue (feeling of tiredness)
Irritability
Eye pain
Headache (pain in head)
Heart rate irregular
Hypoaesthesia (reduced sense of touch or sensation)
Joint swelling
Maculopathy (a condition or disease of the macula, the small spot in the retina where vision is keenest)
Muscular weakness (muscle weakness)
Polydipsia (excessive thirst)

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 5 people, 23.81%
Age-Related Macular Degeneration: 5 people, 23.81%

* Approximation only. Some reports may have incomplete information.

Do you take Ipratropium bromide and Lucentis?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously